A new method for treating lung cancer developed by Israeli company NeoTX is still in the clinical trial phase for advanced solid tumors and is offering real hope to patients with metastatic cancer. Moreover, the company believes its medicine could be a game-changer in the field of oncology.
Follow Israel Hayom on Facebook, Twitter, and Instagram
The "Tumor Targeted Superantigen" (TTS), as the company has named its proprietary technology, works to kill cancer cells in a way that no currently available cancer treatment is able.
TTS "binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor-specific immune cells," according to the company.
If approved after clinical trials, the platform will represent a breakthrough in the ability to attack a variety of cancerous tumors, in accordance with the status of the patient's immune system and the development of the cancerous growth.
Currently, many cancer patients have to undergo chemotherapy treatments that destroy their malignant cells but sometimes damage other parts of the body. In this case, if proven effective, the "Tumor Targeted Superantigen" platform would actually activate the patient's immune system, forcing the disease to withdraw and extend the life of the patient.
In other words, NeoTX aims to extract the immune cells and "turbocharge" them using bacteria, according to CEO and director Asher Nathan.
Working alongside Nathan on the team developing this technology are chief scientist Prof. Roger Kornberg, the 2006 winner of the Nobel Prize in Chemistry; and medical oncologist and NeoTX president Dr. Marcel Rozencweig.
The company recently announced the promotion of current Dr. Scott Fields as its new chief medical officer.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
